Open AccessLong-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial
Author(s) -
Jack Cuzick,
John Forbes,
Ivana Šestak,
Simon Cawthorn,
Hisham Hamed,
Kaija Holli,
Anthony Howell
Publication year - 2007
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djk049
Subject(s) - tamoxifen , medicine , breast cancer , randomization , relative risk , gynecology , placebo , randomized controlled trial , incidence (geometry) , confidence interval , cancer , oncology , pathology , physics , alternative medicine , optics
Initial results from the first International Breast Cancer Intervention Study (IBIS-I) found that tamoxifen reduced the risk of invasive estrogen receptor (ER)-positive tumors by 31% in women at increased risk for breast cancer, but most of the follow-up at this time was during the active treatment phase. We report an updated analysis of IBIS-I that focuses on the period after active treatment was completed, a time for which little evidence from other trials is available.